RUNX2 and breast cancer: In vivo and ex vivo experiments in breast cancer models demonstrate that Runx2 is the key driver that makes cancer cells able to preserve their acquired mechanical properties from the site of the primary tumor to the metastatic sites of softer microenvironments.